Nontyphoid *Salmonella enterica* (NTS) is a common cause of foodborne illnesses worldwide. In industrialized countries, *S. enterica* serovars Enteritidis and Typhimurium are responsible for most NTS infections ([@R1]). In Israel, the distribution of NTS infections differs from the global epidemiology for NTS by having a larger representation of serogroups C1 and C2 (serovars Virchow, Hadar, and Infantis) in addition to serovars Enteritidis and Typhimurium ([@R2]*,*[@R3]).

Analysis of annual trends of NTS infections in Israel during 1995--2009 shows a steady decrease in the incidence of these infections, from 86.9 cases/100,000 persons in 1995 to 31.4/100,000 in 2005. During this period, the predominant serovars were Enteritidis, Typhimurium, Virchow, and Hadar, followed by Infantis. Since 2006, annual incidence of NTS has started to increase, rising to 44.0 cases/100,000 persons in 2009. This trend coincided with a sharp increase in incidence of serovar. Infantis from 1.2 cases/100,000 persons in 2001 to 14.7/100,000 in 2009, a 12-fold rise ([Figure 1](#F1){ref-type="fig"}, panel A). The proportion of serovar Infantis increased from \<10% of NTS in 1995--2005 to 34% in 2009 ([Figure 1](#F1){ref-type="fig"}, panel B). Furthermore, this steep increase in serovar Infantis from clinical (human) sources correlated with an elevated frequency of serovar Infantis from poultry that became apparent after 2006. Serovar Infantis became the predominant serotype in poultry during 2007--2009, while the prevalences of serovars Enteritidis, Typhimurium, Virchow, Bredeney, Newport, and Paratyphi B var. Java decreased ([Figure 1](#F1){ref-type="fig"}, panel C).

![Salmonellosis epidemiology in Israel, 1995--2009. A) Annual incidence of salmonellosis in Israel. Laboratory-confirmed cases of *Salmonella* infections per 100,000 population caused by all *Salmonella* serotypes (black) and by the 5 leading serotypes in Israel. B) The relative contribution (in percentages) of each serotype to the total annual number of *Salmonella* serotypes. *Salmonella* infection incidences were constructed according to the number of human *Salmonella* isolates submitted to the Government Central Laboratories during January 1, 1995--December 31, 2009 (after excluding repeated isolates from the same patient). Data on the Israeli population were derived from the publications of the Israeli Bureau of Statistics. C) Prevalence of *S. enterica* serovar Infantis and other leading serotypes in poultry. The proportion of different *Salmonella* serotypes as percentage from the total *Salmonella* isolates in poultry was analyzed according to routine surveillance in poultry processing plants conducted by veterinary services in 1998--2009. *Salmonella* isolates have been received, identified, and documented in the National *Salmonella* Reference Center of Israel.](10-0100-F1){#F1}

The Study
=========

Molecular analysis was used to study whether the rapid emergence of *S. enterica* ser. Infantis resulted from a general increase in different biotypes or a successful spread of 1 clone. Seventy-one randomly selected isolates of *S. enterica* ser. Infantis identified in Israel during 2007--2009 (21 human sources, 28 poultry sources, and 22 food sources) and 16 historical strains isolated during 1970--2005 (12 human sources, 2 poultry sources, and 2 food sources) were subjected to pulsed-field gel electrophoresis (PFGE). Macrorestriction with the *Xba*I enzyme discriminated the isolates into 23 distinct profiles (pulsotypes), designated I1--I23. Although the historical isolates showed high diversity in their PFGE patterns, most (58/71, 82%) recent (2007--2009) isolates were homogeneous and showed an indistinguishable PFGE profile (pulsotype I1), which was not found among the historical isolates ([Figure 2](#F2){ref-type="fig"}; [Table A1](#TA.1){ref-type="table"}). These results indicate that most of the emerging isolates belong to 1 genetic clone that probably started to spread in Israel sometime during 2005--2007. Furthermore, comparison of the I1 pulsotype with other PFGE profiles through PulseNet ([www.cdc.gov/pulsenet/](http://www.cdc.gov/pulsenet/)) and PulseNet Europe ([www.pulsenetinternational.org/networks/europe.asp](http://www.pulsenetinternational.org/networks/europe.asp)) indicated a pattern not reported elsewhere, suggesting the emerging clone is endemic to Israel.

![Pulsed-field gel electrophoresis (PFGE) patterns of *Salmonella enterica* serovar Infantis isolates from clinical, food, and poultry sources isolated in Israel, 1970--2009, showing a high degree of clonality. Isolate number, year of isolation, and source are indicated. Bracket indicates I1 pulsotype pattern. Macrodigestion performed using *Xba*I restriction enzyme and genetic similarity (in %) was based on dice coefficients. PFGE was conducted according to the standardized *Salmonella* protocol Centers for Disease Prevention and Control PulseNet as described ([@R4]) by using *S. enterica* ser. Braenderup H9812 strain as a molecular size standard. Because of space limitations, only 34/58 pulsotype I1 clones are shown. A complete list is provided in [Table A1](#TA.1){ref-type="table"}.](10-0100-F2){#F2}

To further characterize the isolates, we performed susceptibility tests to 16 antimicrobial compounds. Overall, resistance to 11 antimicrobial agents was detected ([Table](#Ta){ref-type="table"}; [Table A1](#TA.1){ref-type="table"}). Two clear differences were found between the strains isolated before and after 2007. First, although 6/16 (38%) of the historical strains were sensitive to all tested antimicrobial agents and 5/16 (31%) were resistant to only 1 (nitrofurantoin), none of the 2007--2009 isolates were sensitive to all of the tested antimicrobial agents. Most (68/71, 96%) of the recent isolates were resistant to [\>]{.ul}3 antimicrobial agents, which suggests a process of resistance acquisition over time. Second, whereas isolates from 1970--2005 did not share any obvious resistance pattern, most (66/71, 93%) of the 2007--2009 strains showed a combined resistance pattern to nalidixic acid, nitrofurantoin, and tetracycline with or without additional resistance to trimethoprim/sulfamethoxazole ([Table](#Ta){ref-type="table"}). The convergence of the recent serovar Infantis clones to a dominant resistance pattern is consistent with their common PFGE profile and shows that they share high similarity on phenotypic and genotypic levels.

###### Antimicrobial drug resistance patterns of Salmonella enterica serovar Infantis isolates, sorted by isolation year, Israel\*

  Antimicrobial drug resistance profile                                                             PFGE pattern                                             
  ------------------------------------------------------------------------------------------------- -------------- ---- -- --- --- -- ---- --- -- --- --- -- ----
  Ampicillin, cefuroxime, ceftriaxone, cephalothin, nitrofurantoin, trimethoprim/sulfamethoxazole                  1                                         1
  Ampicillin, cefepime, ceftriaxone, cephalothin, cefuroxime, tobramycin                                           1                                         1
  Nitrofurantoin                                                                                                   5                                         5
  Nitrofurantoin, tetracycline                                                                                                 1                             1
  Levofloxacin, nalidixic acid                                                                                                             1                 1
  Nalidixic acid, nitrofurantoin, tetracycline                                                                             1   1      37   3      8   3      53
  Nalidixic acid, nitrofurantoin, tetracycline, cephalothin                                                                                1                 1
  Nalidixic acid, nitrofurantoin, tetracycline, trimethoprim/sulfamethoxazole                                      2       1   1      10          1          15
  Nalidixic acid, tetracycline, trimethoprim/sulfamethoxazole                                                                              1                 1
  Nalidixic acid, tetracycline                                                                                                             1                 1
  Nalidixic acid, trimethoprim/sulfamethoxazole                                                                    1                                         1
  Sensitive to all tested antimicrobial drugs                                                                      6                                         6
  Total                                                                                                            16      2   3      47   7      9   3      87

\*PFGE, pulsed-field gel electrophoresis; I1, emerging PFGE pattern; D, different from the emerging pattern.

Next, we characterized the molecular mechanisms responsible for the common antimicrobial drug--resistance phenotype. In bacteria, an efficient means of acquisition and dissemination of resistance genes is through mobile genetic elements such as plasmids, transposons, or integrons ([@R5]). Plasmid analysis for 15 emerging (2007--2009) and 7 historical (1970--2005) randomly selected isolates demonstrated that all possessed 1 large plasmid of ≈100 kb. To identify antimicrobial drug resistance genes that are possibly encoded on this plasmid, mating experiments were conducted with a plasmid-free, rifampin-resistant *Escherichia coli* J5--3 strain and recent *S. enterica* ser. Infantis isolates harboring tetracycline, nalidixic acid, and nitrofurantoin resistance genes. Conjugation experiments showed the obtained *E. coli* transconjugants received the large (≈100-kb) plasmid and acquired the tetracycline resistance phenotype but remained susceptible to nalidixic acid and nitrofurantoin. We concluded the tetracycline resistance gene(s) is encoded on the conjugative plasmid. Molecular analysis by PCR showed the *tetA* gene encoded within the Tn*1721* transposon in 6 of 6 randomly selected emerging isolates but in only 1 of 5 older historical strains.

We examined class 1 integrons using PCR primers designed to amplify the variable region of class 1 integrons. All 6 recent isolates bore 1 integron with a variable region of ≈1 kb. Sequencing of the resulting amplicon showed the *dfrA1* gene cassette conferring resistance to trimethoprim--sulfamethoxazole followed by the *orfC* gene of unknown function. In contrast, 3/5 historical isolates did not possess any integron, and 2/5 contained a disparate integron with a variable region of ≈1.3 kb. Sequencing analysis indicated a different cassette encoded by the aminoglycoside adenyltransferase *aadA1* gene conferring resistance to spectinomycin and streptomycin.

Resistance to quinolones is often associated with point mutations in the quinolone-resistance determining region of the *gyrA* gene ([@R6]). To examine this possibility, we determined the *gyrA* sequence from 6 recent naladixic acid--resistant and 4 naladixic acid--sensitive isolates. All resistant clones showed the same nucleotide substitution from guanine to thymine at position 259 (G259T) in the *gyrA* gene, resulting in the exchange of asparagine in position 87 to tyrosine (Asp87Tyr) in the quinolone resistance--determining region domain. No mutations were found in the *gyrA* sequence of the naladixic acid--sensitive isolates, suggesting that the Asp87Tyr point mutation is responsible for the observed naladixic acid--resistance phenotype.

Conclusions
===========

It is likely that environmental selective pressure caused by use of antimicrobial drugs has led to the distribution of appropriate resistant genes. Nitrofurans and sulfonamides, for example, have been widely used to treat infections and promote growth of livestock ([@R7]). Because the emerging clone was dominant in all levels of the food chain, including broiler chickens, it is possible that the emerging clone was originally introduced from a poultry source. Recent studies from other countries identified healthy poultry as a potential reservoir of *S. enterica* ser. Infantis ([@R8]*--*[@R10]).

Molecular and phenotypic characterization of recent *S. enterica* ser. Infantis isolates from different sources and regions in Israel showed high homogeneity of emerging isolates that differ genetically and phenotypically from previously isolated strains. We showed that the emerging clone is multidrug resistant and is characterized by a large conjugative plasmid harboring the Tn*1721* transposone and *tetA* gene, which provides reduced susceptibility to tetracyclines. Additional characteristics include a class 1 integron containing the *dfrA1* cassette, a *gyrA* mutation that mediates nalidixic acid resistance and furthers resistance to nitrofurantoin. Our results suggest the recent emergence of serovar Infantis is an outcome of a clonal expansion and establishment of a specific biotype that took place during a relatively short period. Virulence mechanisms contributing to this phenomenon are the subject of an ongoing study.
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###### List of the examined *Salmonella enterica* serovar Infantis isolates, showing source, isolation date, PFGE pattern, and antimicrobial drug susceptibility test results, Israel\*

  Strain no.   Source               Isolation date   PFGE pattern   Susceptibility
  ------------ -------------------- ---------------- -------------- --------------------------------
  335--3       Archive†             1970             I19            S
  12--95       Archive†             1995             I20            S
  852--490     Poultry              1997 Sep 19      I23            nal,sxt
  62376        Clinical (stool)     2000 Oct 24      I22            nal, fd, tet, sxt
  90731        Clinical (stool)     2004 Apr 25      I4             S
  91050        Clinical (stool)     2004 Apr 25      I4             S
  90205        Clinical (stool)     2004 May 5       I4             S
  90206        Clinical (stool)     2004 May 12      I4             S
  90497        Clinical (stool)     2004 Jun 3       I2             amp, rox, ctr, cf, fd, sxt
  90498        Clinical (stool)     2004 Jun 3       I2             amp, fep, ctr, cf, fd, rox, nn
  3228         Food                 2004 Jun 13      I3             fd
  90849        Clinical (stool)     2004 Jun 21      I7             nal, fd, tet, sxt
  91044        Clinical (stool)     2004 Jul 19      I2             fd
  91377        Clinical (stool)     2004 Aug 4       I2             fd
  95286        Poultry              2005 Mar 28      I21            fd
  97258        Food                 2005 Aug 22      I3             fd
  107008       Clinical (stool)     2007 Jan 8       I5             fd, tet
  107195       Clinical (stool)     2007 Jan 15      I1             nal, fd, tet, sxt
  107682       Clinical (stool)     2007 Feb 15      I1             nal, fd, tet
  112303       Poultry              2007 Nov 8       I9             nal, fd, tet
  113264       Poultry              2007 Dec 12      I12            nal, fd, tet, sxt
  113571       Poultry              2008 Jan 7       I1             nal, fd, tet
  114035       Poultry              2008 Jan 29      I1             nal, fd, tet
  114256       Poultry              2008 Feb 17      I1             nal, fd, tet
  114509       Poultry              2008 Mar 9       I1             nal, fd, tet
  115016       Poultry              2008 Apr 13      I8             nal,tet
  115593       Poultry              2008 May 18      I1             nal, fd, tet
  115991       Poultry              2008 Jun 1       I1             nal, fd, tet
  121162       Food                 2008 Sep 8       I1             nal, fd, tet
  118525       Poultry              2008 Sep 10      I14            nal, fd, tet
  118872       Poultry              2008 Oct 5       I13            nal, fd, tet, cf
  121056       Food                 2008 Oct 7       I1             nal, fd, tet, sxt
  121061       Food                 2008 Oct 12      I1             nal, fd, tet
  119297       Poultry              2008 Oct 19      I1             nal, fd, tet
  119305       Poultry              2008 Oct 26      I1             nal, fd, tet
  121078       Food                 2008 Oct 30      I1             nal, fd, tet, sxt
  121080       Food                 2008 Oct 30      I10            nal, fd, tet
  119491       Poultry              2008 Nov 2       I1             nal, fd, tet
  119645       Clinical (stool)     2008 Nov 4       I1             nal, fd, tet
  121093       Food                 2008 Nov 4       I1             nal, fd, tet
  119747       Poultry              2008 Nov 6       I1             nal, fd, tet
  119944       Clinical (stool)     2008 Nov 10      I1             nal, fd, tet
  121102       Food                 2008 Nov 10      I1             nal, fd, tet
  120029       Clinical (stool)     2008 Nov 12      I1             nal, fd, tet
  119815       Poultry              2008 Nov 16      I1             nal, fd, tet
  121116       Food                 2008 Nov 17      I1             nal, fd, tet
  120309       Clinical (stool)     2008 Nov 20      I1             nal, fd, tet
  120187       Poultry              2008 Nov 21      I1             nal, fd, tet, sxt
  120189       Poultry              2008 Nov 21      I1             nal, fd, tet
  120173       Clinical (stool)     2008 Nov 24      I1             nal, fd, tet
  120191       Poultry              2008 Nov 24      I1             nal, fd, tet, sxt
  120186       Clinical (stool)     2008 Nov 25      I1             nal, fd, tet
  120195       Poultry              2008 Nov 27      I1             nal, fd, tet
  120089       Food                 2008 Nov 30      I1             nal, fd, tet
  120091       Food                 2008 Nov 30      I1             nal, fd, tet, sxt
  120094       Food                 2008 Nov 30      I1             nal, fd, tet, sxt
  120096       Food                 2008 Nov 30      I1             nal, fd, tet
  120099       Food                 2008 Nov 30      I1             nal, fd, tet
  120100       Food                 2008 Nov 30      I11            lvx, nal
  120101       Food                 2008 Nov 30      I1             nal, fd, tet
  120102       Food                 2008 Nov 30      I1             nal, fd, tet, sxt
  120103       Food                 2008 Nov 30      I1             nal, fd, tet
  120268       Clinical (stool)     2008 Nov 30      I1             nal, fd, tet
  120314       Poultry              2008 Nov 30      I1             nal, fd, tet
  120321       Poultry              2008 Nov 30      I1             nal, fd, tet
  121135       Food                 2008 Dec 1       I1             nal, fd, tet, sxt
  120229       Poultry              2008 Dec 3       I1             nal, fd, tet, sxt
  120233       Poultry              2008 Dec 3       I1             nal, fd, tet
  120540       Clinical (stool)     2008 Dec 3       I1             nal, fd, tet
  121140       Food                 2008 Dec 3       I16            nal, tet, sxt
  120705       Clinical (stool)     2008 Dec 10      I1             nal, fd, tet
  120895       Clinical (stool)     2008 Dec 17      I6             nal, fd, tet
  120894       Clinical (stool)     2008 Dec 18      I1             nal, fd, tet
  120898       Clinical (stool)     2008 Dec 18      I1             nal, fd, tet, sxt
  113219       Poultry              2008 Dec 27      I1             nal, fd, tet
  123446       Food                 2009 Jan 13      I13            nal, fd, tet
  121937       Poultry              2009 Jan 28      I1             nal, fd, tet
  122727       Food                 2009 Mar 9       I1             nal, fd, tet
  123169       Clinical (abscess)   2009 Apr 3       I1             nal, fd, tet
  122798       Poultry              2009 Apr 5       I1             nal, fd, tet
  122823       Clinical (stool)     2009 Apr 7       I1             nal, fd, tet
  123398       Clinical (stool)     2009 May 3       I18            nal, fd, tet
  123516       Poultry              2009 May 17      I1             nal, fd, tet
  124182       Clinical (blood)     2009 May 26      I1             nal, fd, tet
  123787       Clinical (wound)     2009 Jun 5       I1             nal, fd, tet, sxt
  123844       Food                 2009 Jun 12      I1             nal, fd, tet
  124126       Clinical (stool)     2009 Jun 17      I17            nal, fd, tet

\*Eighty-seven randomly selected *S. enterica* ser. Infantis isolates from human, food, and poultry sources were selected for PFGE analysis and antimicrobial drug susceptibility test. Because *Salmonella* spp. are reportable pathogens in Israel, the strains were submitted to the Government Central Laboratories by various microbiology laboratories throughout Israel. The National *Salmonella* Reference Center did final serologic identification. Isolate number, their source, isolation date, and PFGE pattern are indicated. Antibacterial drug susceptibility was tested by using the VITEK 1 system (bioMérieux S.A., Marcy l\'Etoile, France) and the GNS-210 VITEK card for gram-negative susceptibility testing. *Escherichia coli* ATTC 25922 was used as a reference strain. The tested antibacterial agents were amoxicillin/clavulanic acid; ampicillin (MIC [\>]{.ul}32 μg/mL); rox, cefuroxime; cefepime (MIC [\>]{.ul}32 μg/mL); ceftriaxone (MIC [\>]{.ul}64 μg/mL); cefuroxime (MIC ≥32 μg/mL); cephalothin (MIC [\>]{.ul}32 μg/mL); ciprofloxacin; gentamicin; imipenem; levofloxacin (MIC [\>]{.ul}8 μg/mL); nalidixic acid (MIC [\>]{.ul}32 μg/mL); nitrofurantoin (MIC [\>]{.ul}128 μg/mL); piperacillin/tazobactam; tetracycline (MIC [\>]{.ul}16 μg/mL); tobramycin (MIC [\>]{.ul}16 μg/mL); and trimethoprim/sulfamethoxazole (MIC range 80--320 μg/mL). PFGE, pulsed-field gel electrophoresis; S, sensitive to all examined antibacterial drugs; nal, nalidixic acid; sxt, trimethoprim/sulfamthoxazole; fd, nitrofurantoin; tet, tetracycline; amp, ampicillin; fep, cefepime; ctr, ceftriaxone; cf, cephalothin; nn, tobramycin; lvx, levofloxacin. †National *Salmonella* spp. archive, source unknown.
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